Possibilities of using Urorek® (silodosin, 8 mg) for empirical therapy in patients with lower urinary tract symptoms due to benign prostatic hyperplasia: results of the Russian multicenter observational study MERCURY
- Авторлар: Pushkar D.Y.1,2, Bernikov A.N.1,2, Shvedov A.M.2, Zyryanov A.V.3,4, Feofilov I.V.5, Igoshkin A.V.5,6, Medvedev V.L.7,8, Efremov M.E.7,8, Komyakov B.K.9,10, Fadeev V.A.9
-
Мекемелер:
- FGBOU VO «Russian University of Medicine», Ministry of Health of the Russian Federation
- S.P. Botkin Moscow Multidisciplinary Clinical and Research Center
- Ural State Medical University, Ministry of Health of the Russian Federation
- Sverdlovsk Regional Clinical Hospital No. 1
- Novosibirsk State Medical University, Ministry of Health of the Russian Federation
- Novosibirsk Regional Clinical Hospital
- Kuban State Medical University, Ministry of Health of the Russian Federation
- GBUZ Scientific and Research Institute of Regional Clinical Hospital №1 named after prof. S.V. Ochapovsky
- FGBOU VO North-Western State Medical University named after I.I. Mechnikov
- City Multidisciplinary Hospital No. 2
- Шығарылым: № 4 (2025)
- Беттер: 32-42
- Бөлім: Original Articles
- ##submission.datePublished##: 16.09.2025
- URL: https://journals.eco-vector.com/1728-2985/article/view/690459
- DOI: https://doi.org/10.18565/urology.2025.4.32-42
- ID: 690459
Дәйексөз келтіру
Ашық рұқсат
Рұқсат берілді
Аннотация
Aim. To evaluate the efficiency, safety, and tolerability of Urorek® (silodosin, 8 mg) in empirical therapy of lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH) without prior diagnostic assessment.
Materials and Methods. An open, prospective, multicenter observational study (MERCURY) was carried out in five clinical centers in Russia with the participation of 123 men (114 completed per protocol), aged 50–83 years. Urorek was prescribed empirically to patients with moderate LUTS. Efficacy was assessed using IPSS, QoL, VPSS scores, uroflowmetry parameters (Qmax, Qave), International Index of Erectile Function (IIEF), and hemodynamic parameters. The treatment duration was 90 days.
Results. At day 15, a significant IPSS decrease of 3.77 points was observed; at 1 and 3 months the reduction was 5.63 and 6.86 points, respectively (p < 0.001). QoL, VPSS, Qmax, and Qave improved significantly at all stages. By day 15, Qmax increased by 2.49 ml/s, and by day 91 by 4.74 ml/s (35.5% increase). Adverse events occurred in 1.72% (retrograde ejaculation); no cases of orthostatic hypotension or arrhythmia were recorded. The drug had no significant effect on blood pressure or heart rate.
Discussion. Silodosin demonstrated a rapid and marked effect on both voiding and storage symptoms of BPH, improving quality of life. Efficiency was evident as early as 15 days. VPSS showed strong correlation with IPSS and can be used in elderly or cognitively impaired patients. The drug demonstrated a high safety profile, especially in comorbid patients, and can be prescribed under conditions of limited diagnostic resources.
Conclusion. Urorek® (silodosin, 8 mg) is effective and safe for empirical treatment of LUTS in BPH patients, including elderly and comorbid individuals. Its high selectivity for α1A-adrenergic receptors, low risk of drug-drug interactions, and lack of cardiovascular effects make it a treatment of choice for patients with LUTS/BPH prior to completion of the full diagnostic work-up.
Толық мәтін
Авторлар туралы
Dmitry Pushkar
FGBOU VO «Russian University of Medicine», Ministry of Health of the Russian Federation; S.P. Botkin Moscow Multidisciplinary Clinical and Research Center
Email: pushkardm@mail.ru
ORCID iD: 0000-0002-6096-5723
Academician of RAS, Ph.D., MD, Professor, Chief Urologist of the Ministry of Health of Russia, Chief Urologist of the Moscow Health Department, Head of the Department of Urology; Chief of Moscow Urological Center
Ресей, 127006, Moscow, Dolgorukovskaya str., 4; 125284, Moscow, 2nd Botkinsky proezd, 5Alexander Bernikov
FGBOU VO «Russian University of Medicine», Ministry of Health of the Russian Federation; S.P. Botkin Moscow Multidisciplinary Clinical and Research Center
Хат алмасуға жауапты Автор.
Email: bernikov@mac.com
ORCID iD: 0000-0001-8361-585X
Ph.D., Associate Professor at the Department of Urology; Urologist, Oncologist of Moscow Urological Center
Ресей, 127006, Moscow, Dolgorukovskaya str., 4; 125284, Moscow, 2nd Botkinsky proezd, 5Andrey Shvedov
S.P. Botkin Moscow Multidisciplinary Clinical and Research Center
Email: dr.shvedov135@mail.ru
ORCID iD: 0000-0003-3127-9270
Urologist at Urology Department No. 41 of Moscow Urological Center
Ресей, 125284, Moscow, 2nd Botkinsky proezd, 5Alexander Zyryanov
Ural State Medical University, Ministry of Health of the Russian Federation; Sverdlovsk Regional Clinical Hospital No. 1
Email: zav1965@mail.ru
ORCID iD: 0000-0001-8105-7233
Ph.D., MD, Professor, Head of the Department of Urology, Nephrology and Transplantology; Head of the Regional Urology Center
Ресей, 620028, Yekaterinburg, Repin str., 3; 620102, Yekaterinburg, Volgogradskaya str., 185Igor Feofilov
Novosibirsk State Medical University, Ministry of Health of the Russian Federation
Email: fil_urolog@mail.ru
ORCID iD: 0000-0001-8938-2479
Ph.D., MD, Associate Professor, Chief Urologist of the Ministry of Health of Novosibirsk Region, Chairman of the Novosibirsk Branch of the Russian Urological Society, Honored Doctor of the Russian Federation, Head of the Department of Urology
Ресей, 630091, Novosibirsk, Krasny Prospect, 52Andrey Igoshkin
Novosibirsk State Medical University, Ministry of Health of the Russian Federation; Novosibirsk Regional Clinical Hospital
Email: dr.igoshkin@mail.ru
ORCID iD: 0009-0002-3665-1027
Urologist; Assistant at the Department of Urology
Ресей, 630091, Novosibirsk, Krasny Prospect, 52; 630087, Novosibirsk, Nemirovich-Danchenko str., 130Vladimir Medvedev
Kuban State Medical University, Ministry of Health of the Russian Federation; GBUZ Scientific and Research Institute of Regional Clinical Hospital №1 named after prof. S.V. Ochapovsky
Email: medvedev_vl@mail.ru
ORCID iD: 0000-0001-8335-2578
Ph.D., MD, Professor, Head of the Urology Department; Deputy Chief Physician for Urology
Ресей, 350063, Krasnodar, Mitrofana Sedina str., 4; 350086, Krasnodar, May 1 str., 167Mikhail Efremov
Kuban State Medical University, Ministry of Health of the Russian Federation; GBUZ Scientific and Research Institute of Regional Clinical Hospital №1 named after prof. S.V. Ochapovsky
Email: efremov.uro@yandex.ru
ORCID iD: 0000-0003-2733-0619
Ph.D., Assistant at the Department of Urology; Urologist
Ресей, 350063, Krasnodar, Mitrofana Sedina str., 4; 350086, Krasnodar, May 1 str., 167Boris Komyakov
FGBOU VO North-Western State Medical University named after I.I. Mechnikov; City Multidisciplinary Hospital No. 2
Email: komyakovbk@mail.ru
ORCID iD: 0000-0002-8606-9791
Ph.D., MD, Professor, Head of the Department of Urology; Head of
the Department and Director of the Scientific and Practical Urology
Center
Vladimir Fadeev
FGBOU VO North-Western State Medical University named after I.I. Mechnikov
Email: fad_ur_75@mail.ru
ORCID iD: 0009-0005-0509-037X
Professor at the Department of Urology
Ресей, 191015, St. Petersburg, Kirochnaya str., 41Әдебиет тізімі
- Clinical guidelines of the Ministry of Health of the Russian Federation «Benign Prostatic Hyperplasia». Approved in 2024. Russian (Клинические рекомендации МЗ РФ «Доброкачественная гиперплазия предстательной железы». Год утверждения 2024).
- Djavan B. et al. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 2004;64: 1081.
- Nasu K., Moriyama N., Kawabe K. et al. Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol. 1996;119(5):797–803.
- Tatemichi S., Kobayashi K., Maezawa A. A1-adrenoceptor subtype selectivity and organ specifi city of silodosin (KMD-3213). Yakugaku Zasshi. 2006;126:209–216.
- EAU Guidelines on Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS) 2025.
- Choi W.S., Cho M.C., Lee J.W. et al. Efficacy and safety of silodosin in the treatment of lower urinary tract symptoms in elderly men taking antihypertensive medications. Prostate Int. 2017;5(3):113–118.
- Morganroth J. Effects of the Selective α1A-Adrenoceptor Antagonist Silodosin on ECGs of Healthy Men in a Randomized, Double-Blind, Placeboand Moxifloxacin-Controlled Study Clin Pharmacol & Therapeutics. 2010;87(5):609–613.
- Chapple C.R., Montorsi F., Tammela T.L. et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011;59(3):342–352.
- Montorsi F. Profile of silodosin. Eur Urol Suppl 2010;9(4):491–495.
- Cui Y., Zong H., Zhang Y. The efficacy and safety of silodosin in treating BPH: a systematic review and meta-analysis. Int Urol Nephrol. 2012;44(6):1601–09.
- Novara G. et al. Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data. Br J Urol Int. 2015;115(5);802–814.
- Yuan C., Jian Z., Ma Y. et al. Systematic review and meta-analysis of efficacy and safety of silodosin in treatment of benign prostatic hyperplasia patients with lower urinary tract symptoms. Research Square; 2020. doi: 10.21203/rs.2.23577/v1.
- Osman N.I., Chapple C.R., Tammela T.L., Eisenhardt A., Oelke M. Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH. World J Urol. 2015;33(5):697–706.
- https://go.drugbank.com/drug-interaction-checker дата обращения 18.06.2025
- General characteristics of the drug Urorek dated 07.08.2023. Available at: http://eec.eaeunion.org/. Russian (Общая характеристика лекарственного препарата Урорек от 07.08.2023, http://eec.eaeunion.org/)
- Zimichev A.A., Gusev D.O., Lukyanova D.Yu. Evaluation of the effectiveness of silodosin 8 mg in the treatment of comorbid patients with LUTS/BPH. Urologiia. 2022;6:36–40. Russian (Зимичев А.А., Гусев Д.О., Лукьянова Д.Ю. Оценка эффективности применения препарата силодозин 8 мг в терапии коморбидных пациентов c СНМП/ДГПЖ. Урология. 2022;6:36–40).
- Marks L.S., Gittelman M.C., Hill L.A., Volinn W., Hoel G. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2009;181(6):2634–40.
- Montorsi F., Gandaglia G., Chapple C., Cruz F., Desgrandchamps F., Llorente C. Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study). Int J Urol. 2016;23(7):572–79.
Қосымша файлдар
